DOCSLIB.ORG

Copy of Copy of Drug List 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copy of Copy of Drug List 2012 Page 1 DRUG LIST NAME OTHER NAMES DESCRIPTION 3-methylfentanyl designer drug 6-O-monoacetylmorphine metabolite, heroin 7-aminoclonazepam metabolite, benzodiazepine 7-aminoflunitrazepam metabolite, benzodiazepine 9-hydroxyrisperidone metabolite acebutolol Sectral beta blocker acetaminophen Tylenol, paracetamol analgesic acrivastine Semprex antihistamine acyclovir Zovirax antiviral alpha-hydroxyalprazolam metabolite, benzodiazepine alpha-hydroxymidazolam metabolite, benzodiazepine alpha-hydroxytriazolam metabolite, benzodiazepine alprazolam Xanax benzodiazepine alprenolol Alfeprol beta blocker amantadine Symmetrel antiparkinsonian amiloride Midamor diuretic amiodarone Cordarone, Nexterone, Pacerone antiarrhythmic agent amitriptyline Elavil tricyclic antidepressant amlodipine Norvasc calcium channel blocker amoxapine Asendin tetracyclic antidepressant Page 2 DRUG LIST NAME OTHER NAMES DESCRIPTION amoxicillin antibiotic amphetamine Adderall, Dexedrine stimulant apomorphine Apokyn dopaminergic agonist atenolol Tenormin, Tenoretic beta blocker atorvastatin Lipitor statin (lipitor) atropine anticholinergic aztreonam Azactam antibiotic benazepril Lotensin ACE inhibitor benzatropine Cogentin anticholinergic benzoylecgonine metabolite, cocaine betaxolol Kerlone beta blocker, glaucoma drug biperiden Akineton anticholinergic bisoprolol Ziac, Zebeta beta blocker bromocriptine Cycloset, Parlodel dopaminergic agonist brompheniramine Dimetane, Veltane antihistamine bupivacaine local anesthetic buprenorphine Buprenex opioid bupropion Wellbutrin, Aplenzin, Zyban antidepressant buspirone Buspar anxiolytic agent candesartan Atacand angiotensin II receptor antagonist Page 3 DRUG LIST NAME OTHER NAMES DESCRIPTION captopril Capoten, Capozide ACE inhibitor carbamazepine Tegretol, Equetro, Epitol anticonvulsant carbamazepine-10,11-epoxide metabolite carbinoxamine Palgic antihistamine carisoprodol Soma muscle relaxant carteolol Cartrol beta blocker carvedilol Coreg beta blocker cetirizine Zyrtec antihistamine chloroquine Aralen antimalarial chlorpheniramine antihistamine chlorpromazine Thorazine antipsychotic chlorprothixene Taractan antipsychotic citalopram Celexa, Lexapro antidepressant clemastine Tavist antihistamine clomipramine Anafranil tricyclic antidepressant clonazepam Klonopin benzodiazepine clonidine Catapres antihypertensive clozapine Clozaril, Fazaclo antipsychotic cocaine local anesthetic codeine opioid Page 4 DRUG LIST NAME OTHER NAMES DESCRIPTION cotinine nicotine metabolite cyclizine Marezine antihistamine cyclobenzaprine Flexeril, Amrix muscle relaxant demoxepam benzodiazepine desalkylflurazepam metabolite, benzodiazepine desipramine Norpramin tricyclic antidepressant desmethylcitalopram metabolite desmethylclomipramine metabolite dextromethorphan antitussive diazepam Valium benzodiazepine dihydrocodeine opioid dihydroergotamine Migranal ergot alkaloid diltiazem Cardizem calcium channel blocker diphenhydramine Benadryl antihistamine dipyridamole Persantine, Aggrenox vasodilator disopyramide Norpace antiarrhythmic agent doxapram Dopram respiratory stimulant doxepin Sinequan tricyclic antidepressant doxylamine Unisom, Decapryn antihistamine duloxetine Cymbalta antidepressant Page 5 DRUG LIST NAME OTHER NAMES DESCRIPTION ebastine antihistamine ecgoninemethylester metabolite, cocaine EDDP metabolite, methadone enalapril Vasotec ACE inhibitor ephedrine/pseudoephedrine stimulant, decongestant eprosartan Teveten angiotensin II receptor antagonist ergotamine ergot alkaloid esmolol Brevibloc beta blocker estazolam Prosom benzodiazepine ethosuximide Zarontin anticonvulsant ethylparathion insecticide felbamate Felbatol anticonvulsant, neuroprotectant felodipine Plendil calcium channel blocker fentanyl Sublimaze, Duragesic opioid fexofenadine Allegra antihistamine flecainide Tambocor antiarrhythmic agent fluconazole Diflucan antifungal flunitrazepam Rohypnol benzodiazepine fluoxetine Prozac antidepressant fluphenazine Prolixin antipsychotic Page 6 DRUG LIST NAME OTHER NAMES DESCRIPTION flurazepam Dalmane benzodiazepine fluvoxamine Luvox antidepressant gabapentin Neurontin anticonvulsant galantamine Razadyne Alzheimers treatment glimepiride Amaryl anti diabetic drug glipizide Glucotrol anti diabetic drug haloperidol Haldol antipsychotic hydrocodone Vicodin, Anexsia opioid hydrocortisone corticosteroid hydromorphone Dilaudid opioid hydroxybupropion antidepressant metabolite hydroxychloroquine Plaquenil antimalarial, anti-arthritic hydroxyzine Vistaril antihistamine imipramine Tofranil tricyclic antidepressant indomethacin Indocin NSAID irbesartan Avapro angiotensin II receptor antagonist isocarboxazid Marplan antidepressant, MAO inhibitor isoniazid Rimifon anti tuberculosis drug; MAOI isradipine Dynacirc calcium channel blocker ketamine Ketalar anesthesthetic Page 7 DRUG LIST NAME OTHER NAMES DESCRIPTION ketoprofen Actron NSAID ketorolac Toradol NSAID labetalol Trandate, Normodyne beta blocker lamotrigine Lamictal anticonvulsant levomepromazine Levoprome antipsychotic, discontinued levorphanol/dextrorphan Levo-dromoran opioid / dextromethorphan metabolite lidocaine Xylocaine local anesthetic, antiarrhythmic agent lisinopril Prinivil, Zestril ACE inhibitor loperamide Immodium antidiarrheal loratadine Claritin, Alavert antihistamine lorazepam Atavan benzodiazepine losartan Cozaar angiotensin II receptor antagonist loxapine Loxitane antipsychotic malathion insecticide maprotiline Ludiomil tetracyclic antidepressant MDA 3,4-methylenedioxyamphetamine designer drug MDEA 3,4-methylenedioxyethylamphetamine designer drug MDMA 3,4-methylenedioxymethamphetamine designer drug meclizine Antivert antihistamine medazepam benzodiazepine Page 8 DRUG LIST NAME OTHER NAMES DESCRIPTION meloxicam Mobic NSAID meperidine Demerol, pethidine opioid mepivacaine Carbocaine local anesthetic meprobamate Equanil, Miltown anxiolytic agent mescaline hallucinogen mesoridazine Serentil antipsychotic, discontinued metformin Fortamet, Riomet, Glucophage anti diabetic drug methadone Dolophine, Methadose opioid methamphetamine/phentermine Desoxyn / Adipex stimulant methocarbamol Robaxin muscle relaxant methylphenidate Ritalin stimulant metipranolol Optipranolol beta blocker metoclopramide/chlordiazepoxide Reglan / Librium antiemetic / benzodiazepine metoprolol Lopressor beta blocker metronidazol Flagyl antimicrobial mexiletine Mexitil antiarrhythmic agent miconazole Monistat antifungal midazolam Versed benzodiazepine midodrine Orvaten, Proamatine vasopressor/ antihypotensive minoxidil Rogaine vasodilator Page 9 DRUG LIST NAME OTHER NAMES DESCRIPTION mirtazapine Remeron tetracyclic antidepressant molindone Moban antipsychotic morphine MS Contin opioid morphine-3-β-D-glucuronide metabolite, opioid nalbuphine Nubain opioid naloxone Narcan opiate antagonist naltrexone Revia, Vivitrol opiate antagonist nandrolone Durabolin anabolic steroid nateglinide Starlix anti diabetic drug nefazodone Serzone antidepressant, discontinued nicardipine Cardene calcium channel blocker nicotine tobacco alkaloid nifedipine Procardia, Adalat calcium channel blocker nimodipine Nimotop calcium channel blocker nisoldipine Sular calcium channel blocker nitrazepam Mogadon benzodiazepine norbuprenorphine metabolite, opioid norcyclobenzaprine metabolite nordiazepam metabolite, benzodiazepine nordoxepin metabolite Page 10 DRUG LIST NAME OTHER NAMES DESCRIPTION norfentanyl metabolite, opioid norfluoxetine metabolite normeperidine metabolite normorphine metabolite, opioid norpropoxyphene metabolite norsertraline metabolite nortriptyline/protriptyline Aventyl, Pamelor / Vivactil tricyclic antidepressant ofloxacin Floxin, Levoquin antibiotic olanzapine Zyprexa atypical antipsychotic omeprazol Prilosec, Nexium, Zegerid anti ulcer drug ondansetron Zofran antiemetic orphenadrine Norflex anticholinergic oxazepam Serax benzodiazepine oxcarbazepine Trileptal anticonvulsant oxprenolol Trasicor beta blocker oxycodone Oxycontin, Percodan, Percocet opioid oxymorphone Numorphan opioid paroxetine Paxil, Pexeva antidepressant penbutolol/levobunolol Levatol / Akbeta beta blocker pentazocine Talwin opioid Page 11 DRUG LIST NAME OTHER NAMES DESCRIPTION pentoxifylline Trental, Pentoxil vasodilator pergolide Permax parkinsons drug; ergot derivitive perphenazine Trilafon antipsychotic phenazone analgesic phencyclidine hallucinogen phendimetrazine Bontril, Statobex anorectic phenelzine Nardil antidepressant pheniramine/pirbuterol / Maxair antihistamine / bronchodilator phenmetrazine anorectic, discontinued phenylbutazone Azolid NSAID phenylephrine decongestant phenylpropanolamine decongestant phenytoin Dilantin anticonvulsant physostigmine cholinesterase inhibitor pilocarpin Salagen glaucoma treatment pindolol Visken beta blocker pioglitazon Actos anti diabetic drug piroxicam Feldene NSAID pramipexole Mirapex parkinsons drug prazepam Centrax benzodiazepine Page 12 DRUG LIST NAME OTHER NAMES DESCRIPTION prazosin Minipress antihypertensive prilocaine Citanest local anesthetic primidone Mysoline anticonvulsant procainamide Procan antiarrhythmic agent procaine Novocain local anesthetic prochlorperazine Compazine, Compro neuroleptic, antiemetic procyclidine Kemadrin parkinsons drug progesterone steroid hormone promazine Sparine antipsychotic promethazine Phenergan antiemetic propafenone Rythmol antiarrhythmic agent propoxyphene Darvon opioid propranolol Inderal beta blocker pyrilamine antihistamine quetiapine Seroquel antipsychotic quinapril Accupril ACE inhibitor quinine antipyretic,antimflammatory,antimalarial,an ramipril Altace ACE inhibitor
Load more

Recommended publications
  • Anti-Migraine Agents Reference Number: OH.PHAR.PPA.34 Effective Date: 01.01.21 Last Review Date: 11.20 Line of Business: Medicaid
    Clinical Policy: Anti-Migraine Agents Reference Number: OH.PHAR.PPA.34 Effective Date: 01.01.21 Last Review Date: 11.20 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description • When using a preferred agent where applicable, the number of tablets/doses allowed per month will be restricted based on the manufacturer’s package insert and/or Buckeye Health plans quantity limits. CNS AGENTS: ANTI-MIGRAINE AGENTS – ACUTE MIGRANE TREATMENT NO PA REQUIRED “PREFERRED” STEP THERAPY REQUIRED PA REQUIRED “NON-PREFERRED” “PREFERRED” NARATRIPTAN (GENERIC OF AMERGE®) NURTEC™ ODT (rimegepant) ALMOTRIPTAN (generic of Axert®) RIZATRIPTAN TABLETS (GENERIC OF CAFERGOT® (ergotamine w/caffeine) MAXALT®) ELETRIPTAN (generic of Relpax®) RIZATRIPTAN ODT (GENERIC OF ERGOMAR® (ergotamine) MAXALT-MLT®) FROVA® (frovatriptan) SUMATRIPTAN TABLETS, NASAL SPRAY, MIGERGOT® (ergotamine w/caffeine) INJECTION (GENERIC OF MIGRANAL® (dihydroergotamine) IMITREX®) ONZETRA™ XSAIL™ (sumatriptan) REYVOW™ (lasmiditan) SUMAVEL DOSEPRO® (sumatriptan) TOSYMRA® (sumatriptan) TREXIMET® (sumatriptan/naproxen) UBRELVY™ (ubrogepant)* ZOLMITRIPTAN (generic of Zomig®) ZOLMITRIPTAN ODT (generic of Zomig ZMT®) ZOMIG® NASAL SPRAY (zolmitriptan) CNS AGENTS: ANTI-MIGRAINE AGENTS – CLUSTER HEADACHE TREATMENT NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” VERAPAMIL (Generic of Calan®) EMGALITY™ (galcanezumab) VERAPAMIL SR/ER (Generic of Calan SR®, Isoptin SR®, Verelan®) CNS AGENTS: ANTI-MIGRAINE AGENTS – PROPHYLAXIS TREATMENT NO PA REQUIRED “PREFERRED” STEP THERAPY REQUIRED PA REQUIRED “NON-PREFERRED” (Trials of at least 3 controller “PREFERRED” medications) Cardiovascular Agents: Beta-blockers AIMOVIG™ (erenumab-aooe) † EMGALITY™ (galcanezumab) CNS Agents: Anticonvulsants AJOVY™ (fremanezumab-vfrm) * CNS Agents: Serotonin-norepinephrine reuptake inhibitors CNS Agents: Tricyclic antidepressants †Initial Dose is limited to 70mg once monthly; may request dose increase if 70mg fails to provide adequate relief over two consecutive months.
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Metabolic Changes: Atypical antipsychotic drugs have been associated with These highlights do not include all the information needed to use metabolic changes that may increase cardiovascular/cerebrovascular risk. CLOZARIL safely and effectively. See full prescribing information for These metabolic changes include: CLOZARIL. o Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of CLOZARIL® (clozapine) tablets, for oral use hyperglycemia including polydipsia, polyuria, polyphagia, and Initial U.S. Approval: 1989 weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.9) WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC o Dyslipidemia: Undesirable alterations in lipids have occurred in HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; patients treated with atypical antipsychotics. (5.9) MYOCARDITIS AND CARDIOMYOPATHY; INCREASED o Weight Gain: Significant weight gain has occurred. Monitor weight MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA- gain. (5.9) RELATED PSYCHOSIS • Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and See full prescribing information for complete boxed warning. monitor closely. Assess for co-morbid conditions. (5.10) • Fever: Evaluate for infection and for neutropenia, NMS. (5.11) • Pulmonary Embolism (PE): Consider PE if respiratory distress, chest pain, • Severe Neutropenia: CLOZARIL can cause severe neutropenia, which or deep-vein thrombosis occur. (5.12) can lead to serious and fatal infections. Patients initiating and • Anticholinergic Toxicity: Use cautiously in presence of specific conditions continuing treatment with CLOZARIL must have a baseline blood (e.g., narrow angle glaucoma, use of anticholinergic drugs). (5.13) absolute neutrophil count (ANC) measured before treatment initiation • Interference with Cognitive and Motor Performance: Advise caution when and regular ANC monitoring during treatment (2.1, 5.1).
    [Show full text]
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St
    2014;22(1):13-18 TCP Translational and Clinical Pharmacology http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, Korea *Correspondence: S. Han; Tel: +82-2-2258-7326, Fax: +82-2-2258-7876, E-mail: [email protected] Received 31 May 2014 Primary health care providers play a critical role in maintaining public health, and the appropri- Accepted 31 May 2014 ate use of pharmaceutical products is one of the major parts of their practice. This series of articles, pISSN: 2289-0882 entitled ‘Clinical Pharmacology Review for Primary Health Care Providers,’ is intended to help pri- mary health care providers select more appropriate prescriptions for frequently used drugs based on up-to-date information. We expect that this effort will contribute to improvements in public health and diminish unnecessary drug use. Introduction tion on the H1 receptor.[8] THERAPEU Antihistamines include some of the most frequently prescribed drugs in the primary health care environment for the symp- Generations and Classes tomatic relief of allergic diseases, the common cold, urticaria, Many primary health care providers are well-informed about T and insomnia.[1-5] The importance of antihistamines has been the different ‘generations’ of antihistamines but not about the ICS TU emphasized as the prevalence of target diseases increases.[6,7] different ‘classes’ characterized according to chemical structure. However, the appropriate use, clinical effectiveness, and target [1] This discrepancy seems reasonable because ‘inter-generation’ T populations for prescription of antihistamines are still a matter differences are more prominent than ‘inter-class’ differences.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Nootropic Concepts
    Nootropic concepts intelligent ingredient for gut health Nootropics definition Nootropic is a substance that enhances cognition and memory and facilitates learning. Nootropics work in many ways to produce a range of benefits across memory, focus, attention, motivation, relaxation, mood, alertness, stress resistance. Bluenesse® Bluenesse® – an innovative, exclusive lemon balm extract, Melissa officinalis (L.) – supports your mental health. It has an immediate effect on focus, concentration, and memory. Furthermore, it supports a calm and good mood and helps to balance the stress hormone cortisol. Bluenesse® - Nootropics concepts Nootropic benefits of Bluenesse® and the underlying mode of action: Bluenesse® - Nootropics concepts – detailed information: Several, double blind, randomized, placebo-controlled, crossover human study results have shown that Bluenesse® supports nootropic effects on demand. Below, the investigated parameter and mode of action is explained per each nootropic application. Vital Solutions GmbH, Hausingerstrasse 6, D-40764 Langenfeld, +49 (0) 2173 109 82 02 [email protected] www.vitalsolutions.biz . Nootropic concepts Cognitive performance support and enhancing learning & memory: Bluenesse® significantly improves cognitive performance, particularly alertness, working memory and mathematic processing by improving the efficiency of neuronal communication. It activates Muscarinic receptors, which are responsible for the efficient flow of information between neurological cells, so-called “oscillation”, leading to
    [Show full text]
  • 2-Bromopyridine Safety Data Sheet Jubilant Ingrevia Limited
    2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) Date of Compilation : July 03 ’ 2019 Date of Revision : February 09 ’ 2021 Revision due date : January 2024 Revision Number : 01 Version Name : 0034Gj Ghs01 Div.3 sds 2-Bromopyridine Supersedes date : July 03 ’ 2019 Supersedes version : 0034Gj Ghs00 Div.3 sds 2-Bromopyridine Jubilant Ingrevia Limited Page 1 of 9 2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier PRODUCT NAME : 2-Bromopyridine CAS RN : 109-04-6 EC# : 203-641-6 SYNONYMS : 2-Pyridyl bromide, Pyridine, 2-bromo-, beta-Bromopyridine, o-Bromopyridine SYSTEMATIC NAME : 2-Bromopyridine, -Pyridine, 2-bromo- MOLECULAR FORMULA : C5H4BrN STRUCTURAL FORMULA N Br 1.2. Relevant identified uses of the substance or mixture and uses advised against 1.2.1. Relevant identified uses 2-Bromopyridine is used as an intermediate in the pharmaceutical industry for the manufacture of Atazanavir (an antiretroviral drug), Carbinoxamine, Chloropyramine, triprolidine (antihistamine drugs), Disopyramide Phosphate (an antiarrythmic drug), Mefloquine (antimalarial drug), Pipradrol (mild CNS stimulant) etc. Uses advised against: None 1.3. Details of the supplier of the safety data sheet Jubilant Ingrevia Limited REGISTERED & FACTORY OFFICE: Jubilant Ingrevia Limited Bhartiagram, Gajraula , District: Amroha, Uttar Pradesh-244223, India PHONE NO: +91-5924-252353 to 252360 Contact Department-Safety: Ext. 7424 , FAX NO : +91-5924-252352 HEAD OFFICE: Jubilant Ingrevia Limited, Plot 1-A, Sector 16-A,Institutional Area, Noida, Uttar Pradesh, 201301 - India T +91-120-4361000 - F +91-120-4234881 / 84 / 85 / 87 / 95 / 96 [email protected] -www.jubilantingrevia.com 1.4.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Nootropics for Healthy Individuals
    Trinity College Trinity College Digital Repository Trinity Publications (Newspapers, Yearbooks, The First-Year Papers (2010 - present) Catalogs, etc.) 2015 Nootropics for Healthy Individuals Jin Pyo Jeon Trinity College, Hartford Connecticut, [email protected] Follow this and additional works at: https://digitalrepository.trincoll.edu/fypapers Part of the Chemicals and Drugs Commons Recommended Citation Jeon, Jin Pyo, "Nootropics for Healthy Individuals". The First-Year Papers (2010 - present) (2015). Trinity College Digital Repository, Hartford, CT. https://digitalrepository.trincoll.edu/fypapers/61 Nootropics for Healthy Individuals Jin Pyo Jeon With recent advances in fields like biotechnology and genetic engineering, the concern for a just and equal distribution of human enhancement technologies undoubtedly became one of the most significant ethical dilemmas of the 21st century. And with the sudden rise of cognitive enhancement drug (otherwise called as nootropics) use in society, the need for developing policies to address these dilemmas have now become an urgent issue that the scientific and political community must confront. Once only used by the few with special needs or neurological disorders, nootropics are now being utilized by a significant part of the population for cognitive enhancement, inciting a debate of the regulation and legalization of nootropics. Nonetheless, given the currently known benefits and risks of nootropics, the mechanisms through which nootropics function, and the ineffectiveness of policy restrictions, it would be more pragmatic to inform and allow for the non-prescription uses for some nootropics rather than to restrict its use. Benefits, Risks, and Viability of the Use of Nootropics Among many other nootropics, two drugs have become the de facto nootropics for many healthy individuals: modafinil (commercially known as Provigil) and methylphenidate (commercially known as Ritalin).
    [Show full text]
  • Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T
    Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T. J Pharma Pharma Sci 02: JPPS 122. Case Report DOI:10.29011/2574-7711.100022 Ashwagandha-The Nature’s Gift to Mankind Tanvay Jaithliya* Department of Pharmacy, Mewar University, Gangrar (Chittorgarh), India *Corresponding author: Jaithliya T, Department of Pharmacy, Mewar University, Gangrar (Chittorgarh) India. Tel: +91 01471291148; E-mail: [email protected] Citation: Jaithliya T (2017) Ashwagandha-The Nature’s Gift to Mankind. J Pharma Pharma Sci 02: 122. DOI: 10.29011/2574-7711.100022 Received Date: 15 March, 2017; Accepted Date: 10 April, 2017; Published Date: 17 April, 2017 Withania somnifera commonly known as Ashwagandha, In- Sindh, Gujarat and Rajasthan. It is also found in Nepal, China and dian Ginseng, poison gooseberry or winter cherry is a plant in the Yemen. solanaceae family or night shade family. It is used as one of the most powerful herbs in Ayurvedic healing, has been used since ancient times for a wide variety of conditions, and is most well- known for its restorative benefits. Traditionally, it is believed that a person who consumes this herbal medicine will gain horse like strength and vitality. Pathology Ashwagandha is prone to several pests and diseases. Leaf spot disease caused by alternariaalternata Is the most prevalent disease, which is most severe in the plains of Punjab, Haryana, Jammu and Kashmir and Himachal Pradesh? Bio deterioration of its pharmaceutically active components during leaf spot disease Description has been reported. This species is short, tender perennial shrub growing 14-30 Culinary Use inches tall. Leaves are dull green, elliptic, usually up to 10-12 cm long.
    [Show full text]